These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18006878)

  • 21. Cellular immune responses and occult infection in seronegative heterosexual partners of chronic hepatitis C patients.
    Roque-Cuéllar MC; Sánchez B; García-Lozano JR; Praena-Fernández JM; Núñez-Roldán A; Aguilar-Reina J
    J Viral Hepat; 2011 Oct; 18(10):e541-9. PubMed ID: 21914075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
    Zabaleta A; Arribillaga L; Llopiz D; Dotor J; Lasarte JJ; Prieto J; Borrás-Cuesta F; Esteban JI; Quer J; Vayreda F; Sarobe P
    Antiviral Res; 2007 Apr; 74(1):25-35. PubMed ID: 17275104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses.
    Vajdy M; Selby M; Medina-Selby A; Coit D; Hall J; Tandeske L; Chien D; Hu C; Rosa D; Singh M; Kazzaz J; Nguyen S; Coates S; Ng P; Abrignani S; Lin YL; Houghton M; O'Hagan DT
    J Gen Virol; 2006 Aug; 87(Pt 8):2253-2262. PubMed ID: 16847121
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C virus NS4 protein impairs the Th1 polarization of immature dendritic cells.
    Takaki A; Tatsukawa M; Iwasaki Y; Koike K; Noguchi Y; Shiraha H; Sakaguchi K; Nakayama E; Yamamoto K
    J Viral Hepat; 2010 Aug; 17(8):555-62. PubMed ID: 19804500
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5.
    Lin Y; Kwon T; Polo J; Zhu YF; Coates S; Crawford K; Dong C; Wininger M; Hall J; Selby M; Coit D; Medina-Selby A; McCoin C; Ng P; Drane D; Chien D; Han J; Vajdy M; Houghton M
    J Virol; 2008 Aug; 82(15):7492-503. PubMed ID: 18508900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of cellular immune responses to HCV NS5 protein through in vivo activation of dendritic cells.
    Wintermeyer P; Gehring S; Eken A; Wands JR
    J Viral Hepat; 2010 Oct; 17(10):705-13. PubMed ID: 20002303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses.
    Pillai V; Lee WM; Thiele DL; Karandikar NJ
    J Viral Hepat; 2007 May; 14(5):318-29. PubMed ID: 17439521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins.
    Gerlach JT; Ulsenheimer A; Grüner NH; Jung MC; Schraut W; Schirren CA; Heeg M; Scholz S; Witter K; Zahn R; Vogler A; Zachoval R; Pape GR; Diepolder HM
    J Virol; 2005 Oct; 79(19):12425-33. PubMed ID: 16160170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP
    J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein.
    Zabaleta A; Llopiz D; Arribillaga L; Silva L; Riezu-Boj JI; Lasarte JJ; Borrás-Cuesta F; Prieto J; Sarobe P
    Mol Ther; 2008 Jan; 16(1):210-7. PubMed ID: 17923840
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C.
    Minutello MA; Pileri P; Unutmaz D; Censini S; Kuo G; Houghton M; Brunetto MR; Bonino F; Abrignani S
    J Exp Med; 1993 Jul; 178(1):17-25. PubMed ID: 8100267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccines.
    Koutsoumpli G; Stasiukonyte N; Hoogeboom BN; Daemen T
    Vaccine; 2024 Sep; 42(22):126032. PubMed ID: 38964950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Authentic Patient-Derived Hepatitis C Virus Infects and Productively Replicates in Primary CD4
    Skardasi G; Chen AY; Michalak TI
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29167333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected].
    Lang Kuhs KA; Ginsberg AA; Yan J; Wiseman RW; Khan AS; Sardesai NY; O'Connor DH; Weiner DB
    Mol Ther; 2012 Mar; 20(3):669-78. PubMed ID: 21952169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression.
    Marín MQ; Pérez P; Gómez CE; Sorzano CÓS; Esteban M; García-Arriaza J
    Viruses; 2018 Aug; 10(8):. PubMed ID: 30096846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [DNA immunization with a plasmid containing gene of hepatitis C virus protein 5A (NS5A) induces the effective cellular immune response].
    Masalova OV; Lesnova EI; Grabovetskiĭ VV; Smirnova OA; Ulanova TI; Burkov AN; Ivanov AV; Zaberezhnyĭ AD; Ataullakhanov RI; Kushch AA
    Mol Biol (Mosk); 2010; 44(2):275-83. PubMed ID: 20586188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus.
    Larsson M; Babcock E; Grakoui A; Shoukry N; Lauer G; Rice C; Walker C; Bhardwaj N
    J Virol; 2004 Jun; 78(12):6151-61. PubMed ID: 15163708
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adenovirus-vectored T cell vaccine for hepacivirus shows reduced effectiveness against a CD8 T cell escape variant in rats.
    Hartlage AS; Dravid P; Walker CM; Kapoor A
    PLoS Pathog; 2021 Mar; 17(3):e1009391. PubMed ID: 33735321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4(+) and CD8(+) T-cell responses to hepatitis C virus.
    Capa L; Soriano V; García-Samaniego J; Nuñez M; Romero M; Cascajero A; Muñoz F; González-Lahoz J; Benito JM
    J Med Virol; 2007 May; 79(5):503-10. PubMed ID: 17385690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of sequence variation in a dominant HLA-A*02-restricted epitope in hepatitis C virus on priming and cross-reactivity of CD8+ T cells.
    Ziegler S; Skibbe K; Walker A; Ke X; Heinemann FM; Heinold A; Mok JY; van Esch WJ; Yang D; Wölfl M; Timm J
    J Virol; 2014 Oct; 88(19):11080-90. PubMed ID: 25008925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.